Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 25;64(1):2400192.
doi: 10.1183/13993003.00192-2024. Print 2024 Jul.

An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension

Affiliations

An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension

Hilary M DuBrock et al. Eur Respir J. .

Abstract

Background: Early diagnosis of pulmonary hypertension (PH) is critical for effective treatment and management. We aimed to develop and externally validate an artificial intelligence algorithm that could serve as a PH screening tool, based on analysis of a standard 12-lead ECG.

Methods: The PH Early Detection Algorithm (PH-EDA) is a convolutional neural network developed using retrospective ECG voltage-time data, with patients classified as "PH-likely" or "PH-unlikely" (controls) based on right heart catheterisation or echocardiography. In total, 39 823 PH-likely patients and 219 404 control patients from Mayo Clinic were randomly split into training (48%), validation (12%) and test (40%) sets. ECGs taken within 1 month of PH diagnosis (diagnostic dataset) were used to train the PH-EDA at Mayo Clinic. Performance was tested on diagnostic ECGs within the test sets from Mayo Clinic (n=16 175/87 998 PH-likely/controls) and Vanderbilt University Medical Center (VUMC; n=6045/24 256 PH-likely/controls). In addition, performance was tested on ECGs taken 6-18 months (pre-emptive dataset), and up to 5 years prior to a PH diagnosis at both sites.

Results: Performance testing yielded an area under the receiver operating characteristic curve (AUC) of 0.92 and 0.88 in the diagnostic test sets at Mayo Clinic and VUMC, respectively, and 0.86 and 0.81, respectively, in the pre-emptive test sets. The AUC remained a minimum of 0.79 at Mayo Clinic and 0.73 at VUMC up to 5 years before diagnosis.

Conclusion: The PH-EDA can detect PH at diagnosis and 6-18 months prior, demonstrating the potential to accelerate diagnosis and management of this debilitating disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: H.M. DuBrock and R.P. Frantz report personal fees from Janssen Research and Development, LLC, a Johnson and Johnson company, outside the submitted work; and that additionally, Mayo Clinic may benefit financially from the algorithm described. T.E. Wagner, K. Carlson, C.L. Carpenter, S. Awasthi, M. Babu, A. Prasad, U. Yoo, R. Barve and V. Soundararajan are employees of nference, which received financial support from Janssen Research and Development, LLC, a Johnson and Johnson company, for work on this study. T.E. Wagner, S. Awasthi and V. Soundararajan also have patent application numbers 63/091,715 (non-invasive methods for detection of pulmonary hypertension) and 63/126,331 (systems and methods for diagnosing a health condition based on patient time series data) pending. K. Carlson, C.L. Carpenter, M. Babu, A. Prasad and R. Barve also have a patent application number 63/126,331 (systems and methods for diagnosing a health condition based on patient time series data) pending. Z.I. Attia, P.A. Friedman and S. Kapa have nothing to disclose apart from the fact that Mayo Clinic may financially benefit from the algorithm described in future. A.R. Hemnes, J. Annis and E.L. Brittain have no competing interests to report. S.J. Asirvatham reports personal fees from Abiomed, Atricure, Biotronik, Blackwell Futura, Boston Scientific, Medtronic, Medtelligence, Spectranetics, St. Jude, Zoll, Aegis, ATP, Nevro, Sanovas, Sorin Medical and FocusStart, outside the submitted work; and additionally, Mayo Clinic may financially benefit from the algorithm described in future. S.J. Asirvatham also receives royalties for work licensed through Mayo Clinic to a privately held company for contributions related to the use of nerve signal modulation to treat central, autonomic and peripheral nervous system disorders, including pain. Mayo Clinic receives royalties and owns equity in this company. The company does not currently license or manufacture any drug or device in the medical field. S.J. Asirvatham is a co-patent holder for technique to minimise coagulum formation during radiofrequency ablation. Products/techniques related to the above disclosures are not being discussed in this publication. M. Selej, P. Agron, E. Kogan, D. Quinn, P. Dunnmon and N. Khan are employees of Janssen Research and Development, LLC, a Johnson and Johnson company and own shares in the company.

Figures

None
Summary of the development and validation of the Pulmonary Hypertension (PH) Early Detection Algorithm (PH-EDA) based on analysis of a standard 12-lead ECG. mPAP: mean pulmonary arterial pressure; RHC: right heart catheterisation; TRV: tricuspid regurgitation velocity; VUMC: Vanderbilt University Medical Center; AUC: area under the curve.
FIGURE 1
FIGURE 1
Overview of the analytical plan to train and evaluate performance of a deep learning-based ECG algorithm in detection of pulmonary hypertension (PH). It illustrates the steps taken to train and evaluate the algorithm using ECG data from Mayo Clinic. It is a pre-trained algorithm, i.e. when used at other sites, such as Vanderbilt University Medical Center, it is not re-trained on data from those sites. EHR: electronic health record; RHC: right heart catheterisation.
FIGURE 2
FIGURE 2
Patient flow diagram. Schematic of the dataset creation from Mayo Clinic and Vanderbilt University Medical Center (VUMC). PH: pulmonary hypertension; mPAP: mean pulmonary arterial pressure; RHC: right heart catheterisation; ICD: International Classification of Disease; TRV: tricuspid regurgitation velocity. #: dyspnoea ICD code on or before an eligible ECG and the diagnostic RHC/echocardiogram (for PH-likely patients) or the last screening RHC/echocardiogram (for control patients).
FIGURE 3
FIGURE 3
Receiver operating characteristic curves for the performance of the pulmonary hypertension (PH) early detection algorithm (PH-EDA) to identify patients with PH in ECGs across all four time windows of interest in a, c) all patients and b, d) patients with dyspnoea filter using the test datasets from a, b) Mayo Clinic and c, d) Vanderbilt University Medical Center (VUMC). AUC: area under the curve.
FIGURE 4
FIGURE 4
Sensitivity and specificity of the pulmonary hypertension (PH) early detection algorithm (PH-EDA) to detect PH across all four time windows of interest, in a) all patients and b) patients with dyspnoea, using test sets from Mayo Clinic and Vanderbilt University Medical Center (VUMC).

Comment in

References

    1. Hoeper MM, Humbert M, Souza R, et al. . A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306–322. doi:10.1016/S2213-2600(15)00543-3 - DOI - PubMed
    1. Rose-Jones LJ, McLaughlin VV. Pulmonary hypertension: types and treatments. Curr Cardiol Rev 2015; 11: 73–79. doi:10.2174/1573403X09666131117164122 - DOI - PMC - PubMed
    1. Vonk Noordegraaf A, Chin KM, Haddad F, et al. . Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J 2019; 53: 1801900. doi:10.1183/13993003.01900-2018 - DOI - PMC - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, et al. . 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618–3731. doi:10.1093/eurheartj/ehac237 - DOI - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, et al. . 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61: 2200879. doi:10.1183/13993003.00879-2022 - DOI - PubMed

LinkOut - more resources